Literature DB >> 16984941

Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis.

Jarrod Franklin1, Mark Lunt, Diane Bunn, Deborah Symmons, Alan Silman.   

Abstract

BACKGROUND: The increased mortality observed in patients with rheumatoid arthritis is partly due to an increased occurrence of serious infections. A retrospective study from the Mayo Clinic found that infection risk is increased in rheumatoid arthritis. In particular, serious infection was associated with severe disease and use of corticosteroids. Robust estimates are required from prospective studies of incident cases.
OBJECTIVE: To examine the risk of infection leading to hospitalisation and potential factors associated with this risk in an unselected population of patients with inflammatory polyarthritis.
DESIGN: A prospective cohort study comparing infection incidence in new-onset patients with inflammatory polyarthritis with local population experience. PATIENTS AND METHODS: 2108 patients with inflammatory polyarthritis from a community-based register were studied and followed up annually (median 9.2 years). The rate of hospitalisations for serious infection was compared with the rate of hospitalisations in the regional population. The contribution of potential predictors was assessed by undertaking a within-cohort analysis.
RESULTS: Overall, the incidence of infection was more than two and a half times that of the general population (varying by site). History of smoking, corticosteroid use and rheumatoid factor were found to be significantly independent predictors of infection-related hospitalisation. Patients with inflammatory polyarthritis with all three factors were more than seven times as likely to be hospitalised compared with the rest of the cohort. DISCUSSION: These findings provide background data on the risk of infection associated with rheumatoid arthritis, and are of particular interest given the current awareness of the risk of infection associated with anti-tumour necrosis factoralpha treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16984941      PMCID: PMC1856002          DOI: 10.1136/ard.2006.057265

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

Review 1.  Immunogenetics of severe respiratory infections: models for the development of new therapeutic strategies.

Authors:  Marialuisa Bocchino; Almerico Marruchella; Cesare Saltini
Journal:  Respiration       Date:  2005 Sep-Oct       Impact factor: 3.580

Review 2.  Infections and SLE.

Authors:  Gisele Zandman-Goddard; Yehuda Shoenfeld
Journal:  Autoimmunity       Date:  2005-11       Impact factor: 2.815

3.  Association between smoking and tuberculosis infection: a population survey in a high tuberculosis incidence area.

Authors:  S den Boon; S W P van Lill; M W Borgdorff; S Verver; E D Bateman; C J Lombard; D A Enarson; N Beyers
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

4.  Infections in patients with rheumatoid arthritis treated with biologic agents.

Authors:  Joachim Listing; Anja Strangfeld; Sonja Kary; Rolf Rau; Ulrich von Hinueber; Maria Stoyanova-Scholz; Erika Gromnica-Ihle; Christian Antoni; Peter Herzer; Jörn Kekow; Matthias Schneider; Angela Zink
Journal:  Arthritis Rheum       Date:  2005-11

5.  Estimating the incidence of rheumatoid arthritis: trying to hit a moving target?

Authors:  N Wiles; D P Symmons; B Harrison; E Barrett; J H Barrett; D G Scott; A J Silman
Journal:  Arthritis Rheum       Date:  1999-07

6.  Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial.

Authors:  Yves Vanrenterghem; Johannes P van Hooff; Jean-Paul Squifflet; Kaija Salmela; Paolo Rigotti; Rahul M Jindal; Julio Pascual; Henrik Ekberg; Luis Sanchez Sicilia; John N Boletis; Josep M Grinyo; Manuel Arias Rodriguez
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

7.  The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis.

Authors:  V F Manfredsdottir; T Vikingsdottir; T Jonsson; A J Geirsson; O Kjartansson; M Heimisdottir; S L Sigurdardottir; H Valdimarsson; A Vikingsson
Journal:  Rheumatology (Oxford)       Date:  2006-01-10       Impact factor: 7.580

8.  Pneumocystis carinii pneumonia in Hong Kong: a 10 year retrospective study.

Authors:  M Hui; W T Kwok
Journal:  J Med Microbiol       Date:  2006-01       Impact factor: 2.472

9.  Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy.

Authors:  Frederick Wolfe; Liron Caplan; Kaleb Michaud
Journal:  Arthritis Rheum       Date:  2006-02

10.  Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study.

Authors:  B Hernández-Cruz; M H Cardiel; A R Villa; J Alcocer-Varela
Journal:  J Rheumatol       Date:  1998-10       Impact factor: 4.666

View more
  38 in total

Review 1.  [Infectious pulmonary complications of rheumatic diseases].

Authors:  F Moosig; K Dalhoff
Journal:  Z Rheumatol       Date:  2009-10       Impact factor: 1.372

2.  Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Authors:  Rolina D van Gaalen; Michal Abrahamowicz; David L Buckeridge
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

3.  Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.

Authors:  Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

4.  Assessing immune function by profiling cytokine release from stimulated blood leukocytes and the risk of infection in rheumatoid arthritis.

Authors:  Megan L Krause; John M Davis; Keith L Knutson; Michael A Strausbauch; Michael A Strausbach; Cynthia S Crowson; Terry M Therneau; Peter J Wettstein; Eric L Matteson; Sherine E Gabriel
Journal:  Clin Immunol       Date:  2011-05-30       Impact factor: 3.969

5.  Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis.

Authors:  Leann B Maska; Harlan R Sayles; James R O'Dell; Jeffrey R Curtis; S Louis Bridges; Larry W Moreland; Stacey S Cofield; Ted R Mikuls
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

6.  Association of dialysis modality with risk for infection-related hospitalization: a propensity score-matched cohort analysis.

Authors:  Jean-Philippe Lafrance; Elham Rahme; Sameena Iqbal; Naoual Elftouh; Michel Vallée; Louis-Philippe Laurin; Denis Ouimet
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-16       Impact factor: 8.237

Review 7.  Infection Risk and Safety of Corticosteroid Use.

Authors:  Jameel Youssef; Shannon A Novosad; Kevin L Winthrop
Journal:  Rheum Dis Clin North Am       Date:  2015-10-24       Impact factor: 2.670

Review 8.  Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners.

Authors:  Piyush Ranjan; Avinash Chakrawarty; Archana Kumari; Jitendra Kumar
Journal:  J Clin Diagn Res       Date:  2015-05-01

9.  Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults.

Authors:  Dana W Dunne; Albert Shaw; Linda K Bockenstedt; Heather G Allore; Shu Chen; Stephen E Malawista; Lin Leng; Yuka Mizue; Marta Piecychna; Lin Zhang; Virginia Towle; Richard Bucala; Ruth R Montgomery; Erol Fikrig
Journal:  PLoS One       Date:  2010-06-28       Impact factor: 3.240

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.